-
公开(公告)号:US20190233360A1
公开(公告)日:2019-08-01
申请号:US16376096
申请日:2019-04-05
申请人: Novomer, Inc.
发明人: Jay J. Farmer , Sadesh H. Sookraj
IPC分类号: C07C51/235 , C07D493/08 , C07C67/39 , C07C67/34 , C07C51/353 , C07C63/24 , C07C63/26 , C07C63/16 , C07C69/82
CPC分类号: C07C51/235 , C07C51/353 , C07C63/16 , C07C63/24 , C07C63/26 , C07C67/34 , C07C67/39 , C07C69/82 , C07D493/08 , C07C69/80
摘要: Provided are methods for the production of phthalic acid (PA), isophthalic acid (IP A), terephthalic acid (TP A), and derivatives thereof. The methods are based on the addition of beta propiolactone to furfural or a derivative thereof. Provided are cost effective routes to biobased IP A and derivatives thereof, including terephthalic acid.
-
公开(公告)号:US20180319815A1
公开(公告)日:2018-11-08
申请号:US15773902
申请日:2016-11-03
发明人: Monica L. Guzman , Cesar M. Compadre , Paola E. Ordonez , Mariano Martinez , Michael J. Balick , Darin E. Jones , Flavio G. Gaudio
IPC分类号: C07D493/10
CPC分类号: C07D493/10 , C07D307/93 , C07D493/04 , C07D493/08 , C07D493/18
摘要: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.
-
公开(公告)号:US20180297939A1
公开(公告)日:2018-10-18
申请号:US15925559
申请日:2018-03-19
发明人: Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng
IPC分类号: C07C259/06 , C07D471/04 , C07D417/04 , C07D241/08 , C07D213/56 , C07D233/68 , C07D235/14 , C07D487/10 , C07D471/10 , C07D295/155 , C07D209/44 , A61K31/5377 , A61K31/4439 , A61K31/495 , A61K31/44 , A61K31/417 , A61K31/4184 , A61K31/397 , C07D495/10 , A61K31/407 , A61K31/435 , A61K31/451 , A61K31/4035 , A61K31/277 , A61K31/438 , C07D221/20 , A61K31/185 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D209/46 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , C07D491/10 , C07D487/08 , C07D487/04 , C07D261/18 , C07D257/04 , C07D249/18 , C07D417/12 , C07D241/12 , C07D409/12 , C07D409/04 , C07D405/12 , C07D239/22 , C07D239/20 , C07D235/30 , C07D401/12 , C07D401/04 , C07D333/70 , C07D233/38 , C07D233/36 , C07D231/18 , C07D231/14 , C07D317/68 , C07D215/12 , C07D213/81 , C07D213/75 , C07D401/14
CPC分类号: C07C259/06 , A61K31/185 , A61K31/277 , A61K31/397 , A61K31/4035 , A61K31/407 , A61K31/417 , A61K31/4184 , A61K31/435 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/451 , A61K31/495 , A61K31/5377 , C07D207/10 , C07D207/267 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/46 , C07D211/16 , C07D211/58 , C07D213/56 , C07D213/65 , C07D213/75 , C07D213/81 , C07D215/12 , C07D221/20 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D233/68 , C07D235/14 , C07D235/30 , C07D239/20 , C07D239/22 , C07D241/08 , C07D241/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D277/56 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/68 , C07D333/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D493/08 , C07D495/10 , C07D498/04 , C07D513/10 , Y02A50/393 , Y02A50/411 , Y02A50/481
摘要: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
公开(公告)号:US20180244656A1
公开(公告)日:2018-08-30
申请号:US15737351
申请日:2016-06-24
发明人: Frank Bennett , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Xin Gu , Jack D. Scott , Haiqun Tang , Zhiqiang Zhao , Yuhua Huang , Dexi Yang , Katherine Young , Li Xiao , Zhibo Zhang , Jianmin Fu
IPC分类号: C07D403/10 , A61K31/4184 , C07D401/10 , A61K31/4709 , A61K31/416 , C07D413/10 , A61K31/423 , C07D417/10 , A61K31/428 , C07D417/14 , A61K31/496 , A61K31/5377 , A61K31/454 , C07D471/04 , C07D495/08 , C07D487/10 , A61K31/541 , C07D493/04 , C07D493/08 , C07D453/02 , C07D403/14 , C07D405/14 , A61K31/41 , A61K31/4245 , A61K31/4192 , A61K31/421 , A61K31/4196 , A61K31/198 , A61K31/431 , A61K31/546 , A61K31/4545 , A61K31/439 , A61K31/407 , A61P31/04
CPC分类号: C07D403/10 , A61K31/198 , A61K31/407 , A61K31/41 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/423 , A61K31/4245 , A61K31/428 , A61K31/431 , A61K31/437 , A61K31/4375 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/546 , A61K45/06 , A61P31/04 , C07D401/10 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/10 , C07D493/04 , C07D493/08 , C07D495/08
摘要: The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
-
公开(公告)号:USRE46965E1
公开(公告)日:2018-07-24
申请号:US13924892
申请日:2013-06-24
IPC分类号: C07D307/12 , C07F7/18 , C07D407/06 , C07D407/14 , C07D493/04 , C07D493/08 , C07D493/18 , C07D493/22 , C07D493/20 , C07D317/72 , C07H15/26 , C07C33/42 , A61K31/341 , C07D493/10 , C07D307/28 , C07D307/33
CPC分类号: C07F7/1804 , A61K31/341 , C07C33/423 , C07D307/12 , C07D307/28 , C07D307/33 , C07D317/72 , C07D407/06 , C07D407/14 , C07D493/04 , C07D493/08 , C07D493/10 , C07D493/18 , C07D493/20 , C07D493/22 , C07F7/188 , C07H15/26 , Y02P20/55
摘要: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
-
公开(公告)号:US20180186810A1
公开(公告)日:2018-07-05
申请号:US15906401
申请日:2018-02-27
IPC分类号: C07D493/22 , C07D493/18 , C07D493/08 , C07B57/00 , C07D313/00
CPC分类号: C07D493/22 , C07B57/00 , C07D313/00 , C07D493/08 , C07D493/18
摘要: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
-
7.
公开(公告)号:US10011627B2
公开(公告)日:2018-07-03
申请号:US14917792
申请日:2014-08-19
发明人: Huijuan Zhong , Jianchun Liao , Hongping Yu , Yaochang Xu , Qing Li , Jianghua Chen , Peng Gao , Songliang Tan , Shaobao Wang
IPC分类号: C07H7/06 , C07H9/04 , C07D409/10 , C07D409/14 , A61K31/00 , C07H7/04 , A61K31/7048 , C07D493/08
CPC分类号: C07H7/06 , A61K31/00 , A61K31/7048 , C07D409/10 , C07D409/14 , C07D493/08 , C07H7/04 , C07H9/04
摘要: C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of the compounds, preparation methods thereof, pharmaceutical compositions containing the compounds, and applications thereof are described. Compounds of formula (I) are useful as therapeutic agents, and particularly as sodium-dependent glucose contransporter protein (SGLT) inhibitors.
-
公开(公告)号:US09994584B2
公开(公告)日:2018-06-12
申请号:US15518282
申请日:2015-10-14
IPC分类号: C07D493/08 , C07D247/00 , C07D405/12 , A61K31/496
CPC分类号: C07D493/08 , A61K31/496 , C07D247/00 , C07D405/12
摘要: The present invention provides a process for producing the compound having the structure: comprising (a) reacting a compound having the structure: with a compound having the structure: in the presence of a first organic solvent under conditions sufficient to produce the compound, wherein the first organic solvent is a substituted benzene.
-
公开(公告)号:US09994582B2
公开(公告)日:2018-06-12
申请号:US15192629
申请日:2016-06-24
IPC分类号: C07D493/08 , C07K14/575 , C07D493/22 , C07K16/26 , C07D519/00
CPC分类号: C07D493/08 , C07D493/22 , C07D519/00 , C07K14/575 , C07K16/26
摘要: Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof. Compounds of Formula (A), (B), (C), (D), and (E) are contemplated useful as therapeutics for treating a wide variety of conditions, e.g., including but not limited to, conditions associated with angiogenesis and with CDK8 and/or CDK19 kinase activity. Further provided are methods of inhibiting CDK8 and/or CDK19 kinase activity, methods of modulating the □-catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1-alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using a compound of Formula (A), (B), (C), (D), or (E). Further provided are CDK8 and CDK19 point mutants and methods of use thereof.
-
公开(公告)号:US09988394B2
公开(公告)日:2018-06-05
申请号:US15154304
申请日:2016-05-13
发明人: John S. Kovach , Robert Volkmann , Anthony Marfat
IPC分类号: C07D493/08 , A61K31/495 , A61K31/337 , C07D493/22 , A61K31/496 , A61K9/00 , A61K47/02 , A61K45/06 , A61K31/34
CPC分类号: C07D493/08 , A61K9/0019 , A61K9/0053 , A61K31/337 , A61K31/34 , A61K31/496 , A61K45/06 , A61K47/02 , C07D493/22 , A61K2300/00
摘要: The present invention provides a compound having the structure:
-
-
-
-
-
-
-
-
-